CK Life Sciences loss expands to $186.8m

CK Life Sciences (0775) saw its net loss expand 47.6 percent year-on-year to HK$186.8 million in 2025, with no final dividend declared.

The biotech arm of CK group attributed the expanded loss to HK$66.5 million R&D spending increase, a combination of several non-cash extraordinary and one-off items including a much larger decline in the value of the vineyard portfolio, various provisions, and a gain from the transaction involving the R&D subsidiary Polynoma and Nasdaq-listed TransCode Therapeutics.

Excluding the one-time vineyard disposal net gain in 2024 and the extraordinary items in 2025, its net profit after tax of the commercial businesses was HK$130.8 million, up 48.3 percent from a year ago.

Its revenue inched down 2.04 percent to HK$5.41 billion.

Chairman Victor Li Tzar-kuoi said its reorganisation will make more expertise and funding available for sustained R&D progress, adding that with the ongoing support of commercial businesses, the sharpened strategic focus and enhanced efficiency of its R&D activities will strengthen the outlook for successful scientific development.